Document is current
Any future updates will be listed below
-
Authors
Murthy, Pranav
Narasappa, Nell Namitha
Liang, Xiaoyan
Wu, Xianzhu
Luu, Irene
Jeevan, Jeevitha
Sharma, Sagar
Ross, Alison
Lampenfeld, Caleb
Zahn, Sam
Musial, Thomas
Bone, Jennifer
Nakayama, John
Bartlett, David
Chapman, Jocelyn
Garrido, Greta
Shinners, Nicholas
Sands, Arthur
Blackton, Michael
Wang, Ena
Lotze, Michael
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct05107739 at ClinicalTrials.govDocuments that mention this clinical trial
254 The CBL-B inhibitor, NX-0255, enhances human drug enhanced tumor infiltrating lymphocyte (DeTIL) expansion and T cell function in full-scale runs
https://doi.org/10.1136/jitc-2022-sitc2022.0254
361 Universal expansion of CBL-B-inhibited tumor infiltrating lymphocytes, DeTIL-0255, from women with ovarian cancer: Process validation
https://doi.org/10.1136/jitc-2022-sitc2022.0361
Targeting Cbl-b in cancer immunotherapy
https://doi.org/10.1136/jitc-2022-006007
Negative intracellular regulators of T-cell receptor (TCR) signaling as potential antitumor immunotherapy targets
https://doi.org/10.1136/jitc-2022-005845
671 A phase 1 adoptive cell therapy using drug-enhanced, tumor-infiltrating lymphocytes, DeTIL-0255, in adults with advanced malignancies
https://doi.org/10.1136/jitc-2022-sitc2022.0671
